$70.58
35.84% today
Nasdaq, Oct 20, 10:11 pm CET
ISIN
US15102K1007
Symbol
CELC

Celcuity Inc. Stock News

Neutral
Seeking Alpha
10 minutes ago
Celcuity Inc. (NASDAQ:CELC ) Discusses Additional Results From Phase III VIKTORIA-1 Trial and Insights Into PAM Pathway Targeting October 20, 2025 8:00 AM EDT Company Participants Brian Sullivan - Co-Founder, Chairman & CEO Igor Gorbatchevsky - Chief Medical Officer Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Tara Bancroft - TD Cowen, Research Division Andre...
Positive
Investors Business Daily
about 7 hours ago
Celcuity stock shot a record high Monday after the company said its experimental drug delayed breast cancer progression for over a year.
Positive
Invezz
about 8 hours ago
Biotech stocks are lighting up the tape today, with several clinical-stage companies posting double-digit gains on fresh catalysts. From earnings beats to promising trial data and billion-dollar partnerships, investors are rewarding progress across oncology, immunology, and drug delivery platforms.
Neutral
GlobeNewsWire
3 days ago
MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updates on the status of the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib plus fulvestrant with and without palbociclib versus alpelisib and fulvestrant in adults with ...
Neutral
GlobeNewsWire
3 days ago
MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updated clinical results from the Phase 1 portion of a clinical trial evaluating gedatolisib in combination with Nubeqa® (darolutamide), an androgen receptor inhibitor, in men with mCRPC whose disease had pro...
Neutral
GlobeNewsWire
3 days ago
MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced detailed efficacy and safety results from the PIK3CA wild-type (“WT”) cohort of the Phase 3 VIKTORIA-1 clinical trial of gedatolisib, an investigational pan-PI3K/mTORC1/2 inhibitor, in adults with hormone rec...
Positive
Seeking Alpha
12 days ago
Celcuity (CELC) surges to a $2B valuation on strong phase 3 data for gedatolisib in hormone-positive breast cancer, affirming commercial potential. Gedatolisib shows significant progression-free survival benefits in VIKTORIA-1, with manageable discontinuation rates and a $5B market opportunity targeted by CELC. Recent fundraising and loan facilities secure CELC's cash runway into 2027, supporti...
Neutral
GlobeNewsWire
28 days ago
MINNEAPOLIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that a late breaking abstract reporting clinical data from the Phase 3 VIKTORIA-1 trial has been selected for an oral presentation at the upcoming European Society of Medical Oncology (ESMO) Congress, being ...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today